Category: Merck MilliporeSyndicate content

Ex-Millipore CEO Madaus steps down from Covidien board

February 7, 2014 by Chris Walker

Dr. Martin Madaus, the former CEO of Millipore, is stepping away from Covidien's board to become the CEO of an unnamed company.

Ex-Millipore CEO Madaus steps down from Covidien board

Covidien (NYSE:COV) said Dr. Martin Madaus will step down from its board of directors to take an open CEO position with a privately-owned company.

Misonix gains 19% on swing to black | Wall Street Beat

September 18, 2012 by MassDevice staff

Shares of Misonix gain 19% on Wall Street today after the medical device company reports a swing to 4th-quarter and full-year black. Wall Street Beat

Misonix (NSDQ:MSON) shares are up 19% today after the medical device company swung to black ink for its fiscal 4th quarter and full year.

Farmingdale, N.Y.-based Misonix posted profits of $366,000, or 5¢ per share, on sales of $1.7 million for the 12 months ended June 30 – for a 26.7% top-line gain that helped Misonix swing from a $3.5 million loss during its last fiscal year.

Deal for Millipore starting to pay off for Merck KGaA

February 23, 2011 by Dave Price

German chemical and drug company Merck KGaA forecasts profit growth of up to 45 percent in 2011 as its post-merger Merck Millipore unit forecasts revenue growth of up to 56 percent.


Recently acquired Millipore pumped nearly $900 million in additional revenues into Merck Group KGaA (XETRA:MRK) during the second half of 2010, including a $465 million, fourth-quarter contribution.